Investorerne er langt fra tilfredse med de vægttabsdata, som Zealand Pharma har offentliggjort for nyt middel.

Zealand Pharma's CEO states that the most tolerable drugs will be the next to succeed in the obesity market.

Shares in Zealand Pharma experienced a significant drop on the stock exchange following the release of disappointing data from its weight-loss drug trials.

Despite a significant share price drop, Zealand Pharma's CEO remains optimistic, while Novo Nordisk anticipates competition from cheaper generic versions of its weight-loss drugs entering major markets this year.

Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market  WSJ

Zealand Pharma has released its financial results for the full fiscal year.

Zealand Pharma's shares dropped significantly by 32% following disappointing mid-stage trial results for a weight-loss treatment being developed with Roche.

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial  WSJ